VivoSeq
Oncology

Metastatic or Locally Advanced Unresectable Solid Tumors

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Metastatic or Locally Advanced Unresectable Solid Tumors is an early-stage landscape with 0 programs across 1 company. The most active players are EMD Serono Research & Development Institute, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Active, not recruiting·EMD Serono Research & Development Institute, Inc. logoEMD Serono Research & Development Institute, Inc.·Phase 1·NCT04170153·161 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)